Valeant Pharmaceuticals International Inc. (NYSE:VRX) (TSE:VRX) was downgraded by research analysts at Mizuho from a “neutral” rating to an “underperform” rating in a report issued on Wednesday. They presently have a $11.00 price target on the specialty pharmaceutical company’s stock, down from their previous price target of $25.00. Mizuho’s target price would suggest a potential downside of 35.29% from the company’s current price.

A number of other equities research analysts have also issued reports on the stock. Wells Fargo & Co. reiterated an “underperform” rating and set a $19.50 target price on shares of Valeant Pharmaceuticals International in a report on Wednesday, August 10th. Canaccord Genuity reiterated a “hold” rating and set a $33.00 target price on shares of Valeant Pharmaceuticals International in a report on Thursday, November 3rd. Royal Bank Of Canada increased their target price on shares of Valeant Pharmaceuticals International from $31.00 to $36.00 and gave the stock a “sector perform” rating in a report on Wednesday, August 10th. Deutsche Bank AG initiated coverage on shares of Valeant Pharmaceuticals International in a report on Tuesday, September 20th. They set a “hold” rating and a $30.00 target price on the stock. Finally, TD Securities reiterated a “buy” rating and set a $38.00 target price on shares of Valeant Pharmaceuticals International in a report on Saturday, August 13th. Five investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $39.05.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Shares of Valeant Pharmaceuticals International (NYSE:VRX) traded up 3.18% during midday trading on Wednesday, hitting $17.54. 9,820,618 shares of the stock were exchanged. The company’s market cap is $6.10 billion. Valeant Pharmaceuticals International has a 12 month low of $13.77 and a 12 month high of $119.87. The stock has a 50 day moving average price of $20.02 and a 200-day moving average price of $24.13.

Valeant Pharmaceuticals International (NYSE:VRX) last issued its quarterly earnings data on Tuesday, November 8th. The specialty pharmaceutical company reported $1.55 EPS for the quarter, missing the consensus estimate of $1.78 by $0.23. Valeant Pharmaceuticals International had a positive return on equity of 43.81% and a negative net margin of 22.17%. The company earned $2.48 billion during the quarter, compared to analyst estimates of $2.49 billion. During the same quarter in the prior year, the company posted $2.74 earnings per share. The business’s revenue was down 11.0% compared to the same quarter last year. On average, analysts predict that Valeant Pharmaceuticals International will post $5.44 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2016/11/24/valeant-pharmaceuticals-international-inc-vrx-downgraded-by-mizuho-to-underperform.html.

Several large investors have recently modified their holdings of the company. Legal & General Group Plc increased its stake in shares of Valeant Pharmaceuticals International by 2.8% in the first quarter. Legal & General Group Plc now owns 1,209,137 shares of the specialty pharmaceutical company’s stock worth $31,830,000 after buying an additional 33,247 shares during the period. LPL Financial LLC increased its stake in shares of Valeant Pharmaceuticals International by 65.5% in the first quarter. LPL Financial LLC now owns 91,050 shares of the specialty pharmaceutical company’s stock worth $2,616,000 after buying an additional 36,046 shares during the period. Seven Eight Capital LLC purchased a new stake in shares of Valeant Pharmaceuticals International during the first quarter worth approximately $374,000. Academy Capital Management Inc. TX increased its stake in shares of Valeant Pharmaceuticals International by 13.4% in the third quarter. Academy Capital Management Inc. TX now owns 649,959 shares of the specialty pharmaceutical company’s stock worth $15,956,000 after buying an additional 76,638 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Valeant Pharmaceuticals International by 11.9% in the second quarter. Vanguard Group Inc. now owns 5,917,325 shares of the specialty pharmaceutical company’s stock worth $119,175,000 after buying an additional 631,211 shares during the period. Institutional investors and hedge funds own 64.97% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.